Quantification (science)

GE HealthCare Receives FDA Clearance of a New Deep Learning Solution for Enhanced Image Quality in PET/CT, Advancing its Leadership Position in AI

Retrieved on: 
Tuesday, May 30, 2023
Software, Radiology, Hardware, Health, FDA, Artificial Intelligence, Health Technology, Technology, Omni, CNR, GE HealthCare, Injection, Radiation, NEMA, DL, Molecular imaging, Deep learning, GE, PET, CHO, Quantification (science), Nuclear medicine, Doctor of Philosophy, Time of flight, National Association Medical Staff Services, US, Discovery, Kantonsspital St. Gallen, Acquisition, MD, Patient, Machine learning, AIR, Division, SNR, PET/CT, CR, Liver, AI, US FDA, A, European Journal, European Journal of Nuclear Medicine and Molecular Imaging, Medical imaging, Television, Silviculture, Imaging

GE HealthCare (Nasdaq: GEHC) today announced US FDA 510(k) clearance of Precision DL – a new, revolutionary deep learning-based image processing software included in GE HealthCare’s growing Effortless Recon DL portfolio.

Key Points: 
  • GE HealthCare (Nasdaq: GEHC) today announced US FDA 510(k) clearance of Precision DL – a new, revolutionary deep learning-based image processing software included in GE HealthCare’s growing Effortless Recon DL portfolio.
  • Precision DL provides the image quality performance benefits typically associated with hardware-based Time-of-Flight (ToF) reconstruction, including improved contrast-to-noise ratioi, contrast recoveryi, and quantitative accuracyii.
  • Image quality matters – to the clinician and the patient – making the difference between finding a small lesion early or in its later stages, potentially affecting patient outcomes and disease management.
  • For this reason, clinicians are increasingly adopting AI-based solutions for enhanced image quality compared to that of standard care.

MIRAILAB BIOSCIENCE Inc., the Leading Company in NMN Supplements Announces Health Mailing Kit Series

Retrieved on: 
Thursday, February 2, 2023
Research, Technology, Biotechnology, General Health, University, Health, Data Management, Science, Education, Artificial Intelligence, Postgraduate education, Diet, Stomach cancer, Smoking, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, Mitochondrion, Sugar, Ageing, Biomedicine, Breast cancer, Health status of Asian Americans, Cancer, Organelle, Dyslipidemia, Obesity, Effect, Drinking, Oxygen, Cell, NMN, University of Tokyo, Database, Nutrient, Diabetes, Mouth, Liver cancer, Prostate cancer, NAD, Risk, HQ, Hypertension, Outline of health sciences, Stroke, Lung cancer, Disease, Hiroshima University, Dementia, Quantification (science), Fats, Defense, Washington University in St. Louis, Mail order, Dietary supplement, Palladium, Copper, Nicotinamide mononucleotide

MIRAILAB BIOSCIENCE Inc. (HQ: Tokyo, Japan; CEO: Megumi Tanaka) is proud to announce our new product category: the health mailing kit series.

Key Points: 
  • MIRAILAB BIOSCIENCE Inc. (HQ: Tokyo, Japan; CEO: Megumi Tanaka) is proud to announce our new product category: the health mailing kit series.
  • Just swab your mouth, send us the sample and receive an analysis report informing you of your present and future health.
  • We were the first company in the world to market NMN supplements, and the pioneers of human clinical studies (“Assessment of Effects of Long-term Administration of Nicotinamide Mononucleotide (NMN)”, with Hiroshima University, the Graduate School of Biomedical & Health Sciences.)
  • Soon, we plan to add new products to our lineup of mailing kits and expand to new markets.